Differential tolerance to antinociceptive effects of μ opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats

Psychopharmacology

Volumn 154, Issue 2, 2001, Pages 131-142

  Walker, Ellen A ^a   Young, Alice M ^b  

^a EINSTEIN MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Efficacy; Etonitazene; Etorphine; Morphine; Rat; Tolerance

Indexed keywords

ANTINOCICEPTIVE AGENT; BUPRENORPHINE; ETONITAZENE; MORPHINE; MU OPIATE RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CROSS TOLERANCE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG REEXPOSURE; DRUG TOLERANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TAIL FLICK TEST;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; BENZIMIDAZOLES; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; MALE; MORPHINE; NARCOTICS; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU;

EID: 0035111517     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000620     Document Type: Article

References (54)

1. Tolerance and dependence after continuous morphine infusion from osmotic pumps measured by operant responding in rats
2. Tolerance to the effects of buprenorphine on schedule-controlled behavior and analgesia in rats
3. Non-competitive nature of the antagonistic mechanism responsible for tolerance development to opiate-induced analgesia
4. Clinical actions of fentanyl and buprenorphine
5. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent
6. Differential cross-tolerance to opio-ids in squirrel monkeys responding under a shock titration schedule
7. Buprenorphine: Demonstration of physical dependence liability
8. The effect of intrinsic efficacy on opioid tolerance
9. Behavioral effects of buprenorphine and diprenorphine under a multiple schedule of food presentation in squirrel monkeys
10. Effects of buprenorphine on shock titration in squirrel monkeys
11. 35S]-thio)triphosphate binding
12. Genetic variance in nociception and its relationship to the potency of morphine-induced analgesia in thermal and chemical tests
13. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes
14. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor
15. The development of tolerance to morphine in the rat
16. Opioid analgesics in clinical pain management
17. Discriminative stimulus effects of reversible and irreversible opiate agonists: Morphine, oxymorphazone and buprenorphine
18. Kappa opioids in rhesus monkeys. III. Dependence associated with chronic administration
19. Opioid analgesics and antagonists
20. Studies of the dependence-producing properties of GPA 1657, profadol, and propiram in man
21. Agonist and antagonist actions of buprenorphine on three types of opioid receptor in isolated preparations
22. Regulation of opioid receptor activities
23. Opiate regulation of adenosine 3′, 5′-monophosphate level in neuroblastoma × glioma NG108-15 hybrid cells - Relationship between occupancy and effect
24. Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice
25. Oral self-administration of etonitazene in rhesus monkeys: Use of a fading procedure to establish etonitazene as a reinforcer
26. Etonitaz-ene: An opioid selective for the mu receptor types
27. Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats
28. Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats
29. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa3 analgesia
30. In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method
31. Unidirectional non-cross-tolerance (UNCT) in rats and an apparent dissociation between narcotic tolerance and physical dependence
32. Postoperative pain relief with naloxone. Severe respiratory depression and pain after high dose buprenorphine
33. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in human
34. Mu-opioid receptor-stimulated guanosine-5′-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: Signal transduction mechanisms underlying agonist efficacy
35. Differential cross-tolerance between intrathecal morphine and sufentanil in the rat
36. Time course characteristics of tolerance development to continuously infused antinociceptive agents in rat spinal cord
37. Further demonstration of kappa opioid binding sites in the brain: Evidence for heterogeneity
38. Etonitazene delivered orally serves as a reinforcer for Lewis but not Fischer 344 rats
39. The affinity of morphine for its pharmacologic receptor in vivo
40. The etonitazene-dependent rhesus monkey as a model to study narcotic agonist and antagonist activities
41. Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment
42. Cross-tolerance to etorphine differentiates mu-opioid agonists in a rat tail withdrawal assay
43. Modulation by mu-opioid agonists of guanosine-5′-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells
44. Discriminative stimulus profile of buprenorphine in morphine-dependent pigeons
45. Opioid thermal antinociception in rhesus monkeys: Receptor mechanisms and temperature dependency
46. In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats
47. Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure
48. Tolerance and cross-tolerance to morphine-like stimulus effects of mu opioids in rats
49. In vivo apparent affinity and efficacy estimates for mu opiates in a rat tail-withdrawal assay
50. Acute administration of buprenorphine in humans: Partial agonist and blockade effects
51. Involvement of supraspinal epsilon and mu opioid receptors in inhibition of the tail-flick response induced by etorphine in the mouse
52. Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids
53. Tolerance to morphine-like stimulus effects of mu opioid agonists
54. Discriminative stimulus effects of morphine: Effects of training dose on agonist and antagonist effects of mu opioids